Table 2.
Adverse events by ruxolitinib dose level
| 10 mg bid (N = 6) | 15 mg bid (N = 3) | 25 mg bid (N = 6) | 50 mg bid (N = 6) | Total (N = 21) | |
|---|---|---|---|---|---|
| Hematologic, n (%) | |||||
| Neutropenia | 2 (33.4) | 1 (33.3) | 2 (33.3) | 2 (33.3) | 7 (33.3) |
| Grade 3 | 1 | 1 | 2 | 2 | 6 |
| Grade 4 | 1 | 1 | |||
| Febrile neutropenia | 2 (33.3) | 1 (33.3) | 2 (33.3) | 2 (33.3) | 7 (33.3) |
| Grade 3 | 2 | 1 | 2 | 2 | 7 |
| Lymphocytopenia | 2 (33.3) | 1 (16.7) | 1 (16.7) | 4 (19.0) | |
| Grade 3 | 2 | 1 | 1 | 4 | |
| Thrombocytopenia | 2 (33.3) | 1 (33.3) | 1 (16.7) | 4 (19.0) | |
| Grade 3 | 1 | 1 | 1 | 2 | |
| Grade 4 | 1 | 2 | |||
| Anemia | 1 (16.7) | 1 (33.3) | 1 (16.7) | 3 (14.3) | |
| Grade 3 | 1 | 1 | 1 | 3 | |
| Nonhematologic, n (%) | |||||
| Pneumonia | 3 (50) | 1 (33.3) | 1 (16.7) | 1 (16.7) | 6 (28.6) |
| Grade 3 | 3 | 1 | 1 | 1 | 6 |
| Respiratory failure | 2 (33.3) | 2 (9.5) | |||
| Grade 3 | 1 | 1 | |||
| Grade 4 | 1 | 1 | |||
| Sepsis | 1 (33.3) | 1 (16.7) | 1 (16.7) | 3 (14.3) | |
| Grade 4 | 1 | 1 | 1 | ||
| Squamous cell carcinoma | 2 (33.3) | 2 (9.5) | |||
| Grade 3 | 2 | 2 | |||
| Cellulitis | 1 (16.7) | 1 (16.7) | 2 (9.5) | ||
| Grade 3 | 1 | 1 | |||
| Gastrointestinal bleeding | 1 (33.3) | 1 (16.7) | 2 (9.5) | ||
| Grade 3 | 1 | 1 | |||
| Grade 4 | |||||
| Hypertension | 1 (16.7) | 1 (16.7) | 2 (9.5) | ||
| Grade 3 | 1 | 1 | |||
| Grade 4 | |||||